Ajanta Pharma Limited — Board Meeting, 28-07-2025: Outcome of Board Meeting

Ajanta Pharma's board has approved strong Q1 FY26 consolidated financial results. Revenue from operations jumped 14% to ₹1,303 Cr, while Profit After Tax (PAT) grew 4% to ₹255 Cr. Excluding a forex loss, PAT growth was a robust 12%. The Branded Generics segment rose 9%, with India sales up an impressive 16%. US Generics saw a significant 36% surge. The company continued its strong performance in India, outperforming the market. Healthy cash flow generation also highlighted the quarter.